Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TNFerade: Interim Phase II data

Interim data from a dose-escalation, U.S. Phase II trial in 24 patients showed that TNFerade in combination

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE